Vaccination of older persons against Sars-Cov-2 and cellular immunogenicity for long term protection (participating in the Doetinchem Cohort Study)
Phase 4
Recruiting
- Conditions
- Immuunsysteemcoronaprevention10047438
- Registration Number
- NL-OMON54152
- Lead Sponsor
- RIVM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 160
Inclusion Criteria
• Having participated the ISA study (part of the Doetinchem Cohort Study).
• Willing to receive the SARS-CoV-2 vaccine.
• Willing to give the Informed Consent.
Exclusion Criteria
A potential subject will be excluded from participation in this study when a
person already received the second primary SARS-CoV-2 vaccination more than a
month earlier and has not signed the ICF at T0, T1 or T2.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoints are vaccine-specific (Spike-protein-specific) antibody<br /><br>levels in serum, functional T-cell responses and memory B-cell immunity at a<br /><br>month following the second SARS-CoV-2 vaccination. </p><br>
- Secondary Outcome Measures
Name Time Method